Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

CompletedOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Nintedanib

diagnosed IPF patients initiating treatment with nintedanib

Trial Locations (10)

11527

"Gen. Hosp. of Chest Diseases Sotiria, Univ. Resp. Med.", Athens

26504

Univ. Gen. Hosp. of Patras, Pátrai

41110

General University Hospital of Larissa, Larissa

49100

General Hospital of Kerkyra, Corfu

57010

"A Pulmonology Clinic G.Papanikolaou Hospital Thessaloniki", Thessaloniki

"General Hospital of Thessaloniki G. Papanikolaou", Thessaloniki

68100

University General Hospital of Evros, Alexandroupoli

71100

University Hospital of Heraklion, University Pulmonology Cl, Heraklion

124 62

University General Hospital Attikon, Athens

45 500

Univ. Gen. Hosp. of Ioannina, Ioannina

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03710824 - Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib | Biotech Hunter | Biotech Hunter